Biocon announced that USFDA has completed a pre-approval inspection of its manufacturing facility in Malaysia and issued a Form 483 with 6 observations.

The stock had outperformed the market over the past one month till Feb. 20, 2018, rising 3.81% compared with the Sensex's 5.09% decline.  It outperformed the market in past one quarter, gaining 50.01% as against 1.03% rise in the Sensex.

Shares of the company declined Rs 8.35, or 1.46%, to trade at  Rs 564.00.  The total volume of shares traded  was  19,028 at the BSE (9.19 a.m., Wednesday).